Chimeric Therapeutics : Transformative Portfolio Expansion Presentation

ersonal use only

THE ASX LEADER IN CELL THERAPY

TRANSFORMATIVE

PORTFOLIO EXPANSION

THE CORE-NK PLATFORM

A CLINCALLY VALIDATED, OFF THE SHELF

NATURAL KILLER CELL PLATFORM

CORE-NKPlatform

only
Transformative
use	Portfolio
Expansion
ersonal

1. platform technology

that can be leveraged to develop multiple new therapies

Broadens

Chimeric's reach into 10+

disease areas

including blood cancers and solid tumours

Triples Chimeric's pipeline

adding 5 new cell therapy assets

Ability to further leverage the platform through

partnerships or licensing

Extends Chimeric's clinical development program with 5 new clinical trials by 2023

Propels Chimeric forward as the ASX

leader in cell therapy and as an

emerging global cell therapy company

2

ersonal use only

THE MOST ROBUST AND ADVANCED PORTFOLIO AND PIPELINE IN AUSTRALIA

7

Unique Assets

8

Clinical Trials

by 2023

10+

Disease Areas

only

CHIMERIC PIPELINE DEVELOPMENT STRATEGY

• 2 novel individualized (autologous) CAR T cell therapies
• Exploration of opportunities with alternative cell types and cell sources

Novel Designs

use

T Cells

Individualized

(autologous)

NK Cells

ersonal

CLTX

PhaseCAR1 CART ongoing in brain cancer

Phase 1 Ongoing

CDH17

CAR T

Phase 1 Planned

2022

Off the Shelf

(allogeneic)

4

WHY NATURAL KILLER (NK) CELLS?

ersonal use only

Natural killer cells are superior immune cells

Natural killer cells are part of our immune system and have a natural ability to identify and kill tumour cells. (they're named for this "natural" killing ability)

Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill tumour cells.

Natural killer cells also have fail-safe mechanisms that

Natural Killer (NK) Cell prevent the killing of healthy cells making them ideal for off the shelf platforms.

5